Dr Miriam Stoppard: Common heartburn could be a cancer risk : mirror

As it stated in mirror

Dr Miriam Stoppard: Common heartburn could be a cancer risk

Dr Miriam Stoppard: Common heartburn could be a cancer risk

Heartburn stories have appeared on this page many times.I suffer occasionally from it myself.It's common, worse after a heavy meal and you can suck on an antacid tablet to ease it.But it's crafty.


let alone cancerresearchuk

Lung cancer patients whose tumour has spread to the brain could be spared radiotherapy

Lung cancer patients whose tumour has spread to the brain could be spared radiotherapy

Patients with non-small cell lung cancer which has spread to the brain could be spared whole brain radiotherapy as it makes little or no difference to how long they survive and their quality of life according to a Cancer Research UK-funded clinical trial published today in The Lancet.Around 45,500 people are diagnosed with lung cancer in the UK every year and an estimated 85 per cent of cases are non-small cell lung cancer.Up to 30 per cent of patients with non-small cell lung cancer have the disease spread to the brain."These trial results could help patients with limited time choose how they spend the end of their lives.


as well abc7chicago

Lung cancer vaccine could come to US from Cuba

Lung cancer vaccine could come to US from Cuba

Lung cancer accounts for one in four cancer deaths in the country.But a new inexpensive treatment developed in Cuba could soon be on its way to the U.S.Lung cancer is the number one killer in the U.S. Until now, treatment options have been limited.But researchers are studying a revolutionary treatment for cancer patients and those at high risk, like smokers, even if they are not yet showing signs of the disease.Susan Roney is a successful attorney and a partner in her law firm.She also has a loving family.


furthermore news-medical

HIF-2 inhibitors could be promising target to combat kidney cancer

HIF-2 inhibitors could be promising target to combat kidney cancer

A new class of drugs called HIF-2 inhibitors is more effective and better tolerated than the standard of care drug sunitinib in treating kidney cancer, researchers with the Kidney Cancer Program at Harold C. Simmons Comprehensive Cancer Center have found.HIF-2 inhibitors, which grew out of research begun more than 20 years ago at UT Southwestern Medical Center, work by interfering with processes that fuel the growth of cells.Investigators conducted a pre-clinical trial in mice transplanted with kidney cancer from over 20 patients and showed that the HIF-2 inhibitor PT2399 controlled cancer in half of the tumors, according to a study published in the journal Nature."This is a completely new treatment for kidney cancer.